Jeena Sikho Lifecare Limited has announced its plans to establish a new hospital unit in Ahmedabad, Gujarat, marking another step in the company's healthcare expansion strategy. The announcement was made through a regulatory filing dated February 16, 2026, under Regulation 30 of SEBI listing requirements.

Project Details and Specifications

The proposed hospital facility will be strategically located in Ahmedabad, with comprehensive details outlined for the development:

Strategic Expansion Initiative

The establishment of this new hospital unit represents a significant milestone in Jeena Sikho Lifecare Limited's expansion strategy. The company operates a network of 120+ Ayurveda clinics and hospitals, focusing on integrated healthcare services. This new facility is expected to strengthen the company's presence in Gujarat while expanding its capacity to serve patients across the region.

Healthcare Service Enhancement

The 150-bed facility spanning 1,60,000 square feet will enhance the company's ability to deliver comprehensive healthcare services. The strategic location in Ahmedabad positions the facility to serve a broader patient base in Gujarat, complementing the company's existing network of healthcare facilities. The project aligns with the company's mission of providing integrated healthcare solutions through its Ayurveda-focused approach.

Investment and Timeline

With an estimated investment of ₹1.5 crore, the project demonstrates the company's commitment to expanding its healthcare infrastructure. The company expects to commence operations within 6 months, indicating a focused approach to rapid deployment and service delivery. This timeline suggests efficient project planning and execution capabilities within the organization's expansion framework.

Jeena Sikho Lifecare Limited has delivered outstanding financial performance in Q3FY26, with the ayurvedic healthcare company reporting exceptional growth across all key financial metrics for the quarter ended 31st December 2025. Following these strong results, the company has made available the audio recording of its earnings conference call held on February 9, 2026.

Financial Performance Highlights

The company's financial results demonstrate remarkable improvement, with net profit experiencing substantial growth year-on-year. The strong performance reflects the company's expanding presence in the ayurvedic healthcare sector and effective operational execution.

Nine-Month Performance

For the nine months ended 31st December 2025, the company maintained its strong momentum with significant improvements across all parameters compared to the corresponding period in the previous year.

Segment-wise Performance

The company operates through two primary business segments, both contributing significantly to the overall growth during Q3FY26.

Ayurvedic Products/Medicines Segment:

• Q3FY26 revenue: ₹12,176.52 lacs (vs ₹5,115.23 lacs in Q3FY25)
• Segment result: ₹5,316.32 lacs (vs ₹1,090.21 lacs in Q3FY25)
• Nine-month revenue: ₹29,771.30 lacs (vs ₹14,673.20 lacs)

Ayurvedic Healthcare Services Segment:

• Q3FY26 revenue: ₹9,989.95 lacs (vs ₹6,453.97 lacs in Q3FY25)
• Segment result: ₹4,104.75 lacs (vs ₹1,304.49 lacs in Q3FY25)
• Nine-month revenue: ₹28,808.27 lacs (vs ₹18,308.93 lacs)

Earnings Call and Corporate Communications

Following the announcement of these strong financial results, Jeena Sikho Lifecare Limited conducted an earnings conference call on February 9, 2026, to discuss the Q3FY26 performance with stakeholders. The company has now made the audio recording of this call publicly available on its website, ensuring transparency and accessibility for investors and analysts.

The availability of the earnings call recording demonstrates the company's commitment to maintaining transparent communication with its stakeholders and complying with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Developments and Regulatory Compliance

The company's Board of Directors approved the unaudited standalone and consolidated financial results at their meeting held on February 7, 2026. The Board meeting commenced at 04:05 P.M. (IST) and concluded at 04:35 P.M. (IST). Additionally, the company granted 2,18,875 employee stock options to 1,176 eligible employees under the Jeena Sikho Employee Stock Option Scheme 2025 on January 1, 2026, with an exercise price of ₹2 per option.

Consolidated Results

On a consolidated basis, the company reported net profit of ₹6,659.89 lacs for Q3FY26 compared to ₹1,321.08 lacs in Q3FY25. Consolidated revenue from operations reached ₹22,167.97 lacs versus ₹11,569.20 lacs in the corresponding quarter of the previous year. The consolidated results include the performance of subsidiaries Jeena Green Resources Private Limited and Jeena Sikho International LLC.